Skip to main content
John Bucuvalas, MD, Pediatric Gastroenterology, New York, NY

JohnCBucuvalasMD

Pediatric Gastroenterology • New York, NY

Pediatric Hepatology and Liver Transplantation

Chief, Pediatric Hepatology, Kravis Children's Hospital at Mount Sinai. Vice Chair, Faculty Affairs, Jack and Lucy Clark Department of Pediatrics, Icahn School of Medicine at Mount Sinai

Join to view full profile

Dr. Bucuvalas is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Bucuvalas' full profile

Already have an account?

  • Office

    5 E 98th St
    New York, NY 10029
    Phone+1 212-659-8060
    Fax+1 212-241-2064

Summary

  • I am Chief of the Hepatology and Vice Chair of Faculty Affairs in the Jack and Lucy Clark Department of Pediatrics at the Icahn School of Medicine at Mount Sinai and the Kravis Children's Hospital at Mount Sinai. I also serve as the Director of Solid Organ Transplant Outreach for the Recananti- Miller Transplant Institute. My primary clinical focus is transplant Hepatology and I am board certified in pediatric gastroenterology with a certificate of added qualification in transplant hepatology. My goal is for children with liver disease to live full, meaningful lives. I have been fortunate to experience and be part of the tremendous innovations in care for children with complex and serious liver disease. When I started my career, children with serious liver disease had few options and many died before age 5 years. Now, we have medical and surgical treatments including liver transplantation that have revolutionized our approach. My research efforts have focused on the challenges along the path of the patient to sustained heath including but not limited to wait list management, mitigation of complications and ensuring long term allograft health without complications of immunosuppression. Along the way, I established collaborations and relations with clinical and research leaders both inside and outside the US. I have been equally fortunate with the opportunity to integrate these efforts with learnings from other industries. In 2002, I underwent training in improvement science which in turn combined with my traditional research training gave me the tools to meet my goal. Through learning from patient and family experience and collaborations with colleagues outside of medicine at MIT, Harvard Business School and with urban architects, I gained a better understanding of how diversity of knowledge, team effectiveness, communication and decision-making can make care better and guide researc.

Education & Training

  • Cincinnati Children's Hospital Medical Center
    Cincinnati Children's Hospital Medical CenterResidency, Pediatrics, 1982 - 1986
  • Massachusetts General Hospital
    Massachusetts General HospitalResidency, Pediatrics, 1978 - 1982
  • Harvard Medical School
    Harvard Medical SchoolClass of 1978
  • Harvard College
    Harvard CollegeA.B., Magna Cum Laude, 1970 - 1974

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2018 - 2025
  • OH State Medical License
    OH State Medical License 1982 - 2019
  • American Board of Pediatrics Pediatrics

Awards, Honors, & Recognition

  • Fellow American Society of Transplantation, 2019
  • Top Doctor Castle Connolly
  • Fellow American Association for the Study of Liver Disease, 2015
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Frailty in Children with Liver Disease: A Prospective Multicenter Study  
    Lurz,E, Quammie C, Englesbe M, Alonso EM, Lin HC, Hsu EK, Furuya KN, Gupta NA, Venkat VL, Daniel JF, Leonis MA, Miloh T, Telega GW, Yap J, Menendez J, Book LS, Himes R..., J Pediatr, 1/1/2018
  • The Medication Level Variability Index (MLVI) Predicts Poor Liver Transplant Outcomes: A Prospective Multi-Site Study  
    Shemesh, E., Bucuvalas, J. C., Anand, R., Mazariegos, G. V., Alonso, E. M., Venick, R. S., ...Shneider, B. L., American Journal of Transplantation, 1/1/2017
  • Self-Management Measurement And Prediction Of Clinical Outcomes In Pediatric Transplant  
    Annunziato, R. A., Bucuvalas, J. C., Yin, W., Anand, R., Alonso, E. M., Mazariegos, G. V., . . Shemesh, E., J Pediatr, 1/1/2017
  • Join now to see all

Books/Book Chapters

  • Solid Organ Transplantation in Infants and Children Organ and Tissue Transplantation 
    Chapter: In Pursuit of the �Ideal� Outcome after Pediatric Liver Transplantation. 
    Ng V & Bucuvalas, JEditors: SP Dunn and S Horslen.2017
  • Solid Organ Transplantation in Infants and Children Organ and Tissue Transplantation 
    Chapter: Long term Outcome after Pediatric Liver Transplantation. 
    Fredericks EM & Bucuvalas JCEditors: SP Dunn and S Horslen.2017
  • Textbook of Organ Transplantation 
    Chapter: Pediatric Liver Transplantation 
    Bucuvalas, J. C. and Feng, S.Editors: A. D. Kirk, S. J. Knechtle, C. P. Larsen, J. C. Madsen, T. C. Pearson and S. A. Webber.John Wiley & Sons, Ltd, Oxford, United Kingdom2014
  • Join now to see all

Lectures

  • Development of NIH-sponsored consortium for pediatric liver disease 
    1/1/2017
  • Metabolic Liver Disease- What, Why and When 
    1/1/2015
  • Multi-organ Dysfunction Associated with Pediatric Liver Failure and Solid Organ Transplantation 
    1/1/2015
  • Join now to see all

Press Mentions

  • Low-Resource Neighborhoods Linked to Higher Risk for Pediatric NAFLD
    Low-Resource Neighborhoods Linked to Higher Risk for Pediatric NAFLDNovember 5th, 2022
  • Dynamics of Systemic Inflammation as a Function of Developmental Stage in Pediatric Acute Liver Failure
    Dynamics of Systemic Inflammation as a Function of Developmental Stage in Pediatric Acute Liver FailureJanuary 15th, 2021
  • Hepatotoxicity Following Administration of Onasemnogene Abeparvovec (AVXS-101) for the Treatment of Spinal Muscular Atrophy
    Hepatotoxicity Following Administration of Onasemnogene Abeparvovec (AVXS-101) for the Treatment of Spinal Muscular AtrophyNovember 10th, 2020
  • Join now to see all

Grant Support

  • Immunosuppression Withdrawal for Stable Pediatric Liver Transplant RecipientsNIAID2012–2014
  • Medical Adherence in Children Who Had a Liver TransplantNIDDK2009–2014
  • Calcineurin Inhibitor Minimization And FOXP3+ Tregs Post-TransplantNational Institute Of Diabetes And Digestive And Kidney Diseases2009–2010
  • Biliary Atresia Study (BASIC)National Center For Research Resources2007–2008
  • Biliary Atresia Research Consortium DatabaseNational Center For Research Resources2005–2008
  • Effect Of IGF-1 On Malnourished Children With Cystic FibrosisNational Center For Research Resources1996–2001

Committees

  • Liver and Intestine Committee, UNOS 2013 - 2015
  • Associate Editor, Clinical Liver Disease 2012 - 2017
  • Editorial Board, Heptology 2012 - 2017
  • Pediatric Committee, UNOS 2012 - 2015
  • Member, Transplant Hepatology Committee, American Board of Pediatrics 2004 - 2011
  • Member, Pediatric Gastroenterology Subboard, American Board of Pediatrics 2001 - 2007

Professional Memberships

Dr. John Bucuvalas, Dr. John Bucuvalas, MD, Dr. J Bucuvalas, Dr. John C Bucuvalas